Aarti Drugs
Aarti Drugs Limited, commonly referred to as Aarti Drugs, is a prominent player in the pharmaceutical industry, headquartered in Mumbai, India. Established in 1984, the company has made significant strides in the production of active pharmaceutical ingredients (APIs) and formulations, catering to both domestic and international markets. With a diverse portfolio that includes anti-infectives, analgesics, and cardiovascular medications, Aarti Drugs stands out for its commitment to quality and innovation. The company has achieved several milestones, including regulatory approvals from major global health authorities, which solidify its market position. Recognised for its robust manufacturing capabilities and a strong emphasis on research and development, Aarti Drugs continues to contribute to the healthcare sector, ensuring the availability of essential medicines worldwide.
DitchCarbon Score
How does Aarti Drugs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aarti Drugs's score of 24 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aarti Drugs's reported carbon emissions
In 2023, Aarti Drugs reported total carbon emissions of approximately 135,084,000 kg CO2e, comprising 54,834,000 kg CO2e from Scope 1 and 80,250,000 kg CO2e from Scope 2. The company has set an ambitious target to reduce its Scope 1 and Scope 2 emissions by 50% by 2030, using 2020 as the baseline year. This commitment reflects Aarti Drugs's dedication to sustainability and climate action. In 2022, the total emissions were about 132,234,000 kg CO2e, with Scope 1 emissions at 56,820,000 kg CO2e and Scope 2 emissions at 76,414,000 kg CO2e. The emissions intensity per rupee of turnover for Scope 1 and Scope 2 was reported at approximately 5.33e-06 kg CO2e/INR in 2023, indicating a focus on improving efficiency alongside emissions reductions. Aarti Drugs has not disclosed any Scope 3 emissions data, which typically includes indirect emissions from the supply chain and product use. The company’s climate commitments are not cascaded from a parent organisation, indicating that these targets and data are independently reported. Overall, Aarti Drugs is actively working towards significant emissions reductions, aligning with industry standards for climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 84,380,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 104,966,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aarti Drugs is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
